[1] RODEN M，BERNROIDER E. Hepatic glucose metabolism in humans：its role in health and disease[J] . Best Pract Res Clin Endocrinol Metab，2003，17 (3)：365-383. [2] SUN H B. Drug discovery based on pharmacological interference with glycometabolism[J] . J Chin Pharm Univ(中国药科大学学报)，2006，37 (1)：1-8. [3] KURUKULASURIYA R，LINK J T，MADAR D J，et al. Prospects for pharmacologic inhibition of hepatic glucose production[J] . Curr Med Chem，2003，10 (2)：99-121. [4] BARF T. Intervention of hepatic glucose production. Small molecule regulators of potential targets for type 2 diabetes therapy[J] . Mini Rev Med Chem，2004，4 (8)：897-908. [5] HENKE B R，SPARKS S M. Glycogen phosphorylase inhibitors[J] . Mini Rev Med Chem，2006，6 (8)：845-857. [6] BAKER D J，GREENHAFF P L，TIMMONS J A. Glycogen phosphorylase inhibition as a therapeutic target：a review of the recent patent literature[J] . Expert Opin Ther Pat，2006，16 (4)：459-466. [7] FOSGERAU K，WESTERGAARD N，QUISTORFF B，et al. Kinetic and functional characterization of 1，4-dideoxy-1，4-imino-D-arabinitol：a potent inhibitor of glycogen phosphorylase with anti-hyperglyceamic effect in ob/ob mice[J] . Arch Biochem Biophys，2000，380 (2)：274-284. [8] OIKONOMAOS N G，SCHNIER J B，ZOGRAPHOS S E，et al. Flavopiridol inhibits glycogen phosphorylase by binding at the inhibitor site[J] . J Biol Chem，2000，275 (44)：34566-34573. [9] ZOGRAPHOS S E，OIKONOMAOS N G，TSITSANOU K E，et al. The structure of glycogen phosphorylase b with an alkyl-dihydropyridine-dicarboxylic acid compound，a novel and potent inhibitor[J] . Structure，1997，5 (11)：1413-1425. [10] CHEN J，LIU J，ZHANG L Y，et al. Pentacyclic triterpenes. Part 3：Synthesis and biological evaluation of oleanolic acid derivatives as novel inhibitors of glycogen phosphorylase[J] . Bioorg Med Chem Lett，2006，16 (11)：2915-2919. [11] CHEN J，LIU J，GONG Y C，et al. Synthesis and biological evaluation of ursolic acid derivatives as novel inhibitors of glycogen phosphorylase[J] . J Chin Pharm Univ (中国药科大学学报)，2006，37 (5)：397-402. [12] WEN X A，XIA J，CHENG K G，et al. Pentacyclic triterpenes. Part 5：Synthesis and SAR study of corosolic acid derivatives as inhibitors of glycogen phosphorylases[J] . Bioorg Med Chem Lett，2007，17 (21)：5777-5782. [13] JAKOBS S，FRIDRICH D，HOFEN S，et al. Natural flavonoids are potent inhibitors of glycogen phosphorylase[J] . Mol Nutr Food Res，2006，50 (1)：52-57. [14] VONGELDERN T W，LAI C Q，GUM R J，et al. Benzoxazole benzenesulfonamides are novel allosteric inhibitors of fructose-1，6-bisphosphatase with a distinct binding mode[J] . Bioorg Med Chem Lett，2006，16 (7)：1811-1815. [15] WRIGHT S W，CARLO A A，DANLEY D E，et al. 3-(2-Carboxyethyl)-4，6-dichloro-1H-indole-2-carboxylic acid：An allosteric inhibitor of fructose-1，6-bisphosphatase at the AMP site[J] . Bioorg Med Chem Lett，2003，13 (12)：2055-2058. [16] WRIGHT S W，HAGEMAN D L，MCCLURE L D，et al. Allosteric inhibition of fructose-1，6-bisphosphatase by anilinoquinazolines[J] . Bioorg Med Chem Lett，2001，11 (1)：17-21. [17] VANPOELJE P D，DANG Q，ERION M D. Discovery of fructose-1，6-bisphosphatase inhibitors for the treatment of type 2 diabetes[J] . Curr Opin Drug Discov Devel，2007，10 (4)：430-437. [18] DANG Q，KASIBHATLA S R，REDDY K R，et al. Discovery of potent and specific fructose-1，6-bisphosphatase inhibitors and a series of orally-bioavailable phosphoramidase-sensitive prodrugs for the treatment of type 2 diabetes[J] . J Am Chem Soc，2007，129 (50)：15491-15502. [19] PARKER J C. Glucose-6-phosphatase inhibitors[J] . Drugs Future，2004，29 (10)：1025-1033. [20] ARION W J，CANFIELD W K，CALLAWAY E S，et al. Direct evidence for the involvement of two glucose 6-phosphate-binding sites in the glucose-6-phosphatase activity of intact liver microsomes - Characterization of T1，the microsomal glucose 6-phosphate transport protein by a direct binding assay[J] . J Biol Chem，1998，273 (11)：6223-6227. [21] VERTESY L，KURZ M，PAULUS E F，et al. The chemical structure of mumbaistatin，a novel glucose-6-phosphate translocase inhibitor produced by Streptomyces sp DSM 11641[J] . J Antibiot，2001，54 (4)：354-363. [22] MADSEN P，LUNDBECK J M，JAKOBSEN P，et al. Glucose-6-phosphatase catalytic enzyme inhibitors：synthesis and in vitro evaluation of novel 4，5，6，7-tetrahydro thieno[3，2-c] - and -[2，3-c] pyridines[J] . Bioorg Med Chem，2000，8 (9)：2277-2289. [23] MADSEN P，JAKOBSEN P，WESTERGAARD N，et al. N，N-dibenzyl N′-benzylidenehydrazines：potent competitive glucose-6-phosphatase catalytic enzyme inhibitors[J] . Bioorg Med Chem Lett，2001，11 (16)：2165-2167. [24] KURUKULASURIYA R，LINK J T. Progress towards glucagon receptor antagonist therapy for type 2 diabetes[J] . Expert Opin Ther Pat，2005，15 (12)：1739-1749. [25] MADSEN P，KNUDSEN L B，WIBERG F C，et al. Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists[J] . J Med Chem，1998，41 (26)：5150-5157. [26] KNUDSEN L B，BRAND C L，SIDELMANN U G，et al. NNC 25-2504，a potent glucagon receptor antagonist[J] . Diabetes，2001，50 (Suppl. 2)：309-309. [27] PETERSEN K F，SULLIVAN J T. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans[J] . Diabetologia，2001，44 (11)：2018-2024. [28] LIANG R，ABRARDO L，BRADY E J，et al. Design and synthesis of conformationally constrained tri-substituted ureas as potent antagonists of the human glucagon receptor[J] . Bioorg Med Chem Lett，2007，17 (3)：587-592. [29] KIETZMANN T，GANJAM G K. Glucokinase：old enzyme，new target[J] . Expert Opin Ther Pat，2005，15 (6)：705-713. [30] GRIMSBY J，SARABU R，CORBETT W L，et al. Allosteric activators of glucokinase：potential role in diabetes therapy[J] . Science，2003，301 (5631)：370-373. [31] KAMATA K，MITSUYA M，NISHIMURA T，et al. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase[J] . Structure，2004，12 (3)：429-438. [32] BROCKLEHURST K J，PAYNE V A，DAVIES R A，et al. Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators[J] . Diabetes，2004，53 (3)：535-541. [33] EFANOV A M，BARRETT D G，BRENNER M B，et al. A novel glucokinase activator modulates pancreatic islet and hepatocyte function[J] . Endocrinology，2005，146 (9)：3696-3701. [34] NIKOULINA S E，CIARALDI T P，MUDALIAR S，et al. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes[J] . Diabetes，2000，49 (2)：263-271. [35] UPHUES I，BOSCHER C，HECKEL A，et al. Additive effects of insulin and GSK-3 inhibitors in stimulation of glycogen synthesis in primary rat hepatocytes[J] . Diabetes，2006，55 (Suppl. 1)：304-304. [36] WITHERINGTON J，BORDAS V，GARLAND S L，et al. 5-Aryl-pyrazolo[3，4-b] pyridines：potent inhibitors of glycogen synthase kinase-3 (GSK-3)[J] . Bioorg Med Chem Lett，2003，13 (9)：1577-1580. [37] OLESEN P H，SORENSEN A R，URSO B，et al. Synthesis and in vitro characterization of 1-(4-aminofurazan-3-yl)-5-dialkylaminomethyl 1H-[1，2，3] triazole-4-carboxylic acid derivatives. A new class of selective GSK-3 inhibitors[J] . J Med Chem，2003，46 (15)：3333-3341.